CPSS
Consumer Portfolio Services, Inc.
There isn't enough reported data to score CPSS yet.
MS
Morgan Stanley
MS's fundamentals are strong: revenue grew 16% and earnings per share grew 29%. At 15x earnings, it's trading in line with its usual 14x. Analysts expect earnings growth.
CPSS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| N/A | |
| N/A |
CPSS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CPSS.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
CPSS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 4x | $4.08 | -58% |
| Fair | 6.3x | $6.44 | -34% |
| Current | 9.6x | $9.77 | — |
| Expensive | 11x | $10.91 | +12% |
Historical ranges are pointers, not guarantees.
CPSS's PE is 9.6x, but its earnings don't support one, so it isn't a reliable read right now.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS has the edge over CPSS in the historical PE scenario, which offers more potential upside but is not a forecast.
CPSS Forward outlook
There aren't enough analyst estimates for CPSS to show an outlook.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
CPSS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.02 | +27% |
| Q2 2026 | $0.92 | +15% |
| Q1 2026 | $0.85 | +7.6% |
| Q4 2025 | $0.80 | +1.3% |
| Q3 2025 | $0.80 | -9.1% |
| Q2 2025 | $0.80 | -27% |
| Q1 2025 | $0.79 | -46% |
| Q4 2024 | $0.79 | -56% |
CPSS's earnings per share have fallen from their peak: $1.02 over the past year, against $3.33 in late 2022.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over CPSS on earnings, with more consistent year-over-year improvement.
CPSS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $131.9M | +22% |
| Q2 2026 | $121.4M | +11% |
| Q1 2026 | $112.3M | +5.1% |
| Q4 2025 | $109.4M | +3.9% |
| Q3 2025 | $108.4M | +7.8% |
| Q2 2025 | $109.8M | +14% |
| Q1 2025 | $106.9M | +16% |
| Q4 2024 | $105.3M | +14% |
CPSS's revenue has grown year over year for 20 quarters in a row: $132M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.6% | +1.1 points |
| Q2 2026 | 7.4% | +1.1 points |
| Q1 2026 | 7.2% | +0.8 points |
| Q4 2025 | 6.6% | -0.4 points |
| Q3 2025 | 6.5% | -0.3 points |
| Q2 2025 | 6.3% | -0.6 points |
| Q1 2025 | 6.4% | -0.8 points |
| Q4 2024 | 7% | -3.7 points |
CPSS's operating margin was 7.6% last quarter, up 1.1 points from the same quarter a year ago.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over CPSS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over CPSS on profitability, with a higher operating margin.
CPSS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $94.2M | +11% |
| Q2 2026 | $105.9M | +95% |
| Q1 2026 | $83M | +13% |
| Q4 2025 | $75.7M | +11% |
| Q3 2025 | $84.9M | +22% |
| Q2 2025 | $54.3M | +26% |
| Q1 2025 | $73.4M | +40% |
| Q4 2024 | $67.9M | +22% |
CPSS has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
CPSS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -165K shares |
| 1 year | -3% | -726K shares |
| 3 years | -7.5% | -1.9M shares |
| 5 years | -2.3% | -559K shares |
CPSS has the edge over MS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5.2M |
| Q2 2026 | $2.5M |
| Q1 2026 | $1.2M |
| Q4 2025 | $2.6M |
| Q3 2025 | $981,000 |
| Q2 2025 | $5.1M |
| Q1 2025 | — |
| Q4 2024 | — |
CPSS spent $11M buying back its own shares over the past year, up 86% from the year before.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has 1.6B diluted shares, down 1.5% from a year ago.
CPSS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 118.9x | High |
| Q2 2026 | 119.1x | High |
| Q1 2026 | 115.7x | High |
| Q4 2025 | 115.4x | High |
| Q3 2025 | 112.6x | High |
| Q2 2025 | 111.2x | High |
| Q1 2025 | 108.4x | High |
| Q4 2024 | 107.5x | High |
CPSS's net debt is more than 20 years of its operating earnings (EBITDA), up from more than 20 years a year ago. Net leverage isn't a meaningful measure for financial services companies like CPSS.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS has the edge over CPSS on leverage, with a lower net debt burden relative to earnings.
CPSS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.7 | Neutral |
| Stochastic | 88.7 | Overbought |
CPSS's weekly RSI is 55 (neutral) and its Stochastic is 89 (overbought).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
CPSS PE vs Financial Services Sector
| Metric | CPSS | Sector median | Relative |
|---|---|---|---|
| PE | 9.6x | 13x | 26% below |
| PE % | 72 | 63 | 9 pts above |
CPSS has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
CPSS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.64 | 1.3% above |
| 20 week MA | $9.49 | 3% above |
| 50 week MA | $9.12 | 7.1% above |
| 100 week MA | $9.15 | 6.8% above |
| 200 week MA | $9.42 | 3.7% above |
CPSS has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
CPSS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.37 | $4.24 | +26% |
| 2021 | $4.24 | $8.94 | +111% |
| 2022 | $8.94 | $8.53 | -4.6% |
| 2023 | $8.53 | $9.37 | +9.8% |
| 2024 | $9.37 | $10.5 | +12% |
| 2025 | $10.5 | $9.13 | -13% |
| 2026 YTD | $9.13 | $9.77 | +7% |
CPSS has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.